Internal Medicine, Endocrinology, Diabetes, & Metabolism · Hialeah, FL
NPI
1285791350
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
7000 W 12th Ave Ste 22
Hialeah, FL, 33014
Phone (305) 820-9650
Groups this clinician bills Medicare through
Medicare paid, 2024
$26K
295 services
Medicare patients, 2024
128
Average age 72
Drug cost, 2024
$2.6M
6,429 prescriptions
Company payments, 2025
$2,183
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sofia E Vasquez was code 99214 (office e&m - established), 138 times for 83 patients. In total Sofia E Vasquez billed 295 services in 12 codes, and Medicare paid $26K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-10-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 138 | 83 | $88.93 | $12K |
| 99232 Hospital E&M - Subsequent | Facility | 82 | 26 | $65.56 | $5,376 |
| 99223 Hospital E&M - Initial | Facility | 30 | 26 | $131.81 | $3,954 |
| 99204 Office E&M - New | Office | 13 | 13 | $94.14 | $1,224 |
By year: 2022 $33K for 367 services; 2023 $24K for 252 services; 2024 $26K for 295 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sofia E Vasquez prescribed most often to Medicare patients was Ozempic (Semaglutide), with 550 prescriptions and refills. In total Sofia E Vasquez wrote 6,429 Medicare prescriptions that cost $2.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 550 | 638 | 93 | $602K |
| Synthroid Levothyroxine Sodium | 423 | 973 | 114 | $44K |
| Metformin Hcl Generic | 342 | 874 | 115 | $1,527 |
| Novolog Flexpen Insulin Aspart | 304 | 414 | 69 | $60K |
| Levothyroxine Sodium Generic | 286 | 789 | 99 | $2,790 |
| Jardiance Empagliflozin | 279 | 451 | 60 | $266K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 247 | 429 | 78 | $21K |
| Mounjaro Tirzepatide | 236 | 268 | 37 | $282K |
| Farxiga Dapagliflozin Propanediol | 230 | 360 | 54 | $203K |
| Atorvastatin Calcium Generic | 218 | 584 | 83 | $1,536 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 211 | 332 | 48 | $24K |
| Tresiba Flextouch U-100 Insulin Degludec | 184 | 274 | 36 | $99K |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | 177 | 283 | 35 | $132K |
| Metformin Hcl Er Metformin Hcl | 160 | 446 | 57 | $821 |
| Rosuvastatin Calcium Generic | 138 | 368 | 48 | $1,450 |
Brand drugs: 3,838 claims; generic drugs: 1,958 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sofia E Vasquez $2,183 ($2,183 in general payments such as food, travel and fees) from 19 companies. The largest payer was Insulet Corporation with $494.
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation PODD | 4 | $494 |
| Novo Nordisk Inc NVO | 6 | $409 |
| Dexcom, Inc. DXCM | 5 | $235 |
| Corcept Therapeutics CORT | 4 | $208 |
| Amgen Inc. AMGN | 5 | $204 |
| Medtronic, Inc. MDT | 5 | $144 |
| Amneal Pharmaceuticals LLC AMRX | 4 | $70.97 |
| Mannkind Corporation MNKD | 2 | $69.48 |
| Sanofi-Aventis U.S. LLC SNY | 3 | $68.15 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $47.17 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.